The Problem
AI agents for medicinal scientists.
Giving failed drugs a second chance.
Most drugs don't fail because the molecule was wrong. They fail because ADMET liabilities go undetected too late — after synthesis cycles have been spent, after assay budgets are exhausted, after the program moves on.
ReForgeX deploys AI agents that work alongside medicinal scientists and DMPK teams — predicting ADMET liabilities before synthesis, designing prodrug strategies to rescue them, and learning from every experiment your lab runs.
The result: compounds that were shelved get a second look. Programs that were stalling move forward. Molecules that almost made it — do.
Science
An AI agent that never
stops learning.
ReForgeX deploys an AI agent inside your DMTA cycle — predicting liabilities before synthesis, recommending the next compound after every assay, and retraining on your program's own data as results come in.
It doesn't replace your scientists. It works alongside them — absorbing every data point, compressing every cycle, and directing the next experiment toward the highest-value target.
AI agent proposes next compounds ranked by predicted ADMET improvement and synthesizability.
Your team synthesizes the top candidates, with synthesis feasibility scored in advance.
Assay results upload directly to ReForgeX — no manual entry, no data loss between cycles.
Agent retrains on new data. Uncertainty shrinks. Cycle accelerates. Program-specific models improve with every run.
Who It's For
Built for the teams
doing real discovery.
Early Access
Ready to compress
your next DMTA cycle?
We're working with a small number of discovery teams. Tell us about your program and we'll be in touch.
We reach out within 48 hours.